Vistin Pharma ASA

OB:VISTN Stock Report

Market Cap: NOK 1.0b

Vistin Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OB:VISTN Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
26 Sep 24BuyNOK 1,410,000Saga Pure ASACompany50,000NOK 28.20
13 Sep 24BuyNOK 6,282,499Saga Pure ASACompany250,000NOK 25.13
23 Aug 24BuyNOK 6,750,001Saga Pure ASACompany300,000NOK 22.50
22 Mar 24SellNOK 11,667,917Pactum ASCompany527,960NOK 22.10

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of VISTN?
Owner TypeNumber of SharesOwnership Percentage
Public Companies700,0001.58%
Private Companies5,743,53113%
Institutions9,025,55720.4%
General Public12,144,47527.4%
Individual Insiders16,731,02937.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 72.61% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
28.4%
Øyvin Brøymer
12,575,000NOK 285.5m0%no data
8.66%
Holmen Fondsforvaltning Ltd.
3,842,055NOK 87.2m0%7.84%
6.75%
Pactum AS
2,991,773NOK 67.9m0%19.44%
3.88%
MP Pensjon PK
1,719,848NOK 39.0m0%0.46%
3.51%
Oystein Spetalen
1,557,930NOK 35.4m0%no data
2.78%
Ferncliff Listed DAI AS
1,234,280NOK 28.0m0%no data
1.69%
Storkleiven AS
751,000NOK 17.0m0%no data
1.69%
August Ringvold Agenturer AS
750,315NOK 17.0m0%no data
1.62%
Lucellum AS
720,000NOK 16.3m0%no data
1.58%
Saga Pure ASA
700,000NOK 15.9m600%no data
1.36%
Henrik Haavie
601,516NOK 13.7m0%no data
1.24%
Ivar Loges
550,000NOK 12.5m0%no data
1.19%
Tom Staavi
526,324NOK 11.9m0%no data
1.15%
Cortex As
508,989NOK 11.6m0%no data
1.13%
Wem Invest AS
500,000NOK 11.3m0%no data
1.06%
DNB Asset Management AS
471,881NOK 10.7m0%no data
1.06%
Sanden Equity AS
468,947NOK 10.6m0%no data
0.92%
Delta A/S
410,000NOK 9.3m0%no data
0.9%
Ginko As
400,000NOK 9.1m0%no data
0.68%
Niels Aall
301,658NOK 6.8m0%no data
0.64%
Nicolai Eger
284,040NOK 6.4m0%no data
0.32%
Kjell-Erik Nordby
140,000NOK 3.2m0%no data
0.17%
Vegard Heggem
77,360NOK 1.8m0%no data
0.17%
Magnus Tolleshaug
75,000NOK 1.7m0%no data
0.09%
Hilde Hagen
40,000NOK 908.0k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/20 12:24
End of Day Share Price 2025/01/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vistin Pharma ASA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mikkel Nyholt-SmedsengCarnegie Investment Bank AB